Uroplasty Inc.
5420 Feltl Road
Minnetonka,
MN 55343
United States - Map
Phone: 952-426-6140
Fax: 952-426-6199
Web Site: http://www.uroplasty.com
| Uroplasty, Inc., a medical device company, engages in the development, manufacture, and marketing of products for the treatment of voiding dysfunctions. The company offers Urgent PC system, a minimally invasive and office-based neurostimulation therapy for the treatment of urinary symptoms, such as urinary urgency, urinary frequency, and urge incontinence associated with overactive bladder; and Macroplastique, a minimally invasive, implantable soft tissue urethral bulking agent for the treatment of adult female stress urinary incontinence. It also provides PTQ Implants, which offer minimally-invasive and soft-textured permanent implant for treatment of fecal incontinence; and VOX Implants, a tissue bulking material for otolaryngology vocal cord rehabilitation applications, as well as distributes wound care products. The company offers its products primarily to urologists, urogynecologists, and gynecologists through direct field sales personnel and independent sales representatives in the United States, as well as through direct sales organization in the United Kingdom and the Netherlands, and through distributors in other markets. Uroplasty, Inc. was incorporated in 1992 and is headquartered in Minnetonka, Minnesota. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. David B. Kaysen , 58
Chief Exec. Officer, Pres and Exec. Director |
N/A
| N/A | Mr. Mahedi Jiwani , 61
Chief Financial Officer, Principal Accounting Officer, VP and Treasurer |
N/A
| N/A | Ms. Susan Hartjes Holman , 55
Chief Operating Officer and Corp. Sec. |
N/A
| N/A | Mr. Arie J. Koole , 45
Controller and Managing Director of The Netherlands |
N/A
| N/A | Mr. Larry Heinemann , 57
VP of Global Sales |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 0.00%
Profile
